Avalo Therapeutics (AVTX) CFO executes Rule 10b5-1 stock sale plan

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported open-market sales of Avalo common stock in early April 2026. He sold a total of 15,959 shares over two days at prices around $15.858 to $17.5674 per share, in multiple transactions.

The filing notes these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025. Following the transactions, Sullivan directly holds 17,338 shares of Avalo Therapeutics common stock.

Insights

Avalo’s CFO executes pre-planned stock sales but retains a meaningful share position.

Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported net open-market sales of 15,959 shares of common stock across four trades on April 1–2, 2026. Reported sale prices ranged from about $15.858 to $17.5674 per share.

The transactions were made under a Rule 10b5-1 trading plan adopted on November 12, 2025, indicating they were pre-scheduled rather than timed opportunistically. There are no derivative holdings shown in this filing, and after the sales he directly holds 17,338 shares.

Because the trades are pre-planned and the filing provides no data on Avalo’s overall share count or valuation impact, these sales look like routine insider portfolio management rather than a clear signal about the company’s outlook.

Insider Trade Summary 10b5-1

Net Seller: 15,959 shares ($270,593)

Net Sell 4 txns

Insider Sullivan Christopher Ryan

Role Chief Financial Officer

Sold 15,959 shs ($271K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,200	$17.0247	$106K
Sale	Common Stock	1,780	$17.5674	$31K
Sale	Common Stock	500	$15.858	$8K
Sale	Common Stock	7,479	$16.8259	$126K

Holdings After Transaction: Common Stock — 19,118 shares (Direct)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The reported securities were sold in multiple transactions at prices ranging from $15.24 to $16.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The reported securities were sold in multiple transactions at prices ranging from $16.45 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The reported securities were sold in multiple transactions at prices ranging from $16.385 to $17.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The reported securities were sold in multiple transactions at prices ranging from $17.39 to $17.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Key Figures

Total shares sold: 15,959 shares Shares sold on April 1, 2026: 7,979 shares Shares sold on April 2, 2026: 7,980 shares +4 more

7 metrics

Total shares sold 15,959 shares Net open-market sales reported in Form 4

Shares sold on April 1, 2026 7,979 shares Two sales of 7,479 and 500 shares

Shares sold on April 2, 2026 7,980 shares Two sales of 6,200 and 1,780 shares

Sale price example (April 1) $15.858 per share One of the reported transaction prices

Sale price example (April 2) $17.5674 per share One of the reported transaction prices

Post-transaction holdings 17,338 shares Common stock directly owned after final sale

Trading plan adoption date November 12, 2025 Rule 10b5-1 trading plan for these sales

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, multiple transactions, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

multiple transactions financial

"The reported securities were sold in multiple transactions at prices ranging from..."

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 03:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Christopher Ryan

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		S⁽¹⁾		500	D	$15.858⁽²⁾	32,797	D
Common Stock	04/01/2026		S⁽¹⁾		7,479	D	$16.8259⁽³⁾	25,318	D
Common Stock	04/02/2026		S⁽¹⁾		6,200	D	$17.0247⁽⁴⁾	19,118	D
Common Stock	04/02/2026		S⁽¹⁾		1,780	D	$17.5674⁽⁵⁾	17,338	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

2. The reported securities were sold in multiple transactions at prices ranging from $15.24 to $16.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

3. The reported securities were sold in multiple transactions at prices ranging from $16.45 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

4. The reported securities were sold in multiple transactions at prices ranging from $16.385 to $17.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

5. The reported securities were sold in multiple transactions at prices ranging from $17.39 to $17.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

	/s/ Christopher Sullivan	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How many Avalo Therapeutics (AVTX) shares did the CFO sell?

Avalo Therapeutics CFO Christopher Ryan Sullivan sold a total of 15,959 shares of common stock. The trades occurred over two days in multiple open-market transactions at prices between about $15.858 and $17.5674 per share, according to the Form 4 filing.

On what dates did Avalo Therapeutics (AVTX) CFO Sullivan sell shares?

Christopher Ryan Sullivan’s reported sales of Avalo Therapeutics common stock took place on April 1 and April 2, 2026. The Form 4 details four separate open-market transactions in that two-day window, each with different share amounts and execution prices.

What prices did Avalo Therapeutics (AVTX) shares sell for in the CFO’s trades?

The reported Avalo Therapeutics CFO stock sales occurred at prices around $15.858 to $17.5674 per share. Footnotes note broader price ranges for individual trade slices, spanning from $15.24 up to $17.80 across multiple transactions executed on those two days.

How many Avalo Therapeutics (AVTX) shares does the CFO still own after these sales?

After the reported sales, Christopher Ryan Sullivan directly holds 17,338 shares of Avalo Therapeutics common stock. This remaining stake is disclosed in the Form 4 as the total number of shares beneficially owned following the last reported transaction on April 2, 2026.

Were Avalo Therapeutics (AVTX) CFO stock sales under a Rule 10b5-1 plan?

Yes. A footnote states the Avalo Therapeutics CFO’s transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 12, 2025. Such plans pre-schedule trades, which typically reduces the significance of the precise timing of these insider stock sales.

What type of transactions did the Avalo Therapeutics (AVTX) CFO execute?

The Form 4 reports four open-market sales of Avalo Therapeutics common stock, each coded as an “S” transaction. All were non-derivative sales of common shares, with no accompanying option exercises, tax-withholding entries, gifts, or derivative transactions disclosed in this filing.